Abivax to present obefazimod phase 3 data at UEG meeting in October

PARIS - Abivax SA (Euronext Paris:FR0012333284 - ABVX / Nasdaq: ABVX), a clinical-stage biotech company with a market capitalization of $6.25 billion, announced Tuesday that data from its phase 3 trials of obefazimod for ulcerative colitis will be presented at the United European Gastroenterology (UEG) Congress in Berlin next month. According to InvestingPro analysis, the company’s stock has shown remarkable momentum, delivering over 1,000% returns year-to-date.

The late-breaking abstract, titled "Efficacy of Obefazimod in ABTECT Phase 3 Induction Trials: Results of 8-Week Therapy in Subsets of Patients With and Without Prior Inadequate Response to Advanced Therapies," will be presented on October 6 by Silvio Danese.

The presentation will focus on the drug’s efficacy in treating moderately to severely active ulcerative colitis, particularly examining patient subgroups based on their previous response to other advanced therapies.

"The acceptance of the late-breaking abstract for presentation at UEG underscores the potential of obefazimod as a new therapeutic option for patients with ulcerative colitis," said Fabio Cataldi, Chief Medical Officer of Abivax, according to the company’s press release.

In addition to the data presentation, Abivax will host an analyst and investor call on October 6 to discuss the findings. The company will also hold a symposium titled "From Evolution to Revolution: New Mechanisms in Ulcerative Colitis" the same day.

Abivax is a clinical-stage biotechnology company focused on developing treatments for chronic inflammatory diseases. Its lead candidate, obefazimod, is currently in Phase 3 clinical trials for ulcerative colitis treatment.

The UEG Congress, one of the largest gastroenterology meetings in Europe, will take place from October 4-7, 2025, providing Abivax an opportunity to showcase its data to specialists in the field.

In other recent news, Abivax has launched a $400 million public offering of American Depositary Shares (ADSs), with a provision for underwriters to purchase additional shares. This development follows Piper Sandler’s decision to raise Abivax’s stock price target to $112, maintaining an Overweight rating due to promising Phase 3 data for obefazimod in ulcerative colitis. Piper Sandler has adjusted its financial models to reflect increased revenue potential in early-line ulcerative colitis treatment, projecting significant earnings growth by 2035. Additionally, Guggenheim has reiterated a Buy rating on Abivax with a $101 price target, emphasizing the potential of its inflammatory bowel disease treatments. Meanwhile, JMP Securities has maintained a Market Outperform rating for Rapport Therapeutics, setting a price target of $77. This comes as Rapport’s stock has risen by 49% year-to-date, driven by strong clinical trial outcomes. These updates reflect the evolving landscape in the biotechnology sector, with significant investor interest in therapeutic advancements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.